Targeted Cancer Therapy with a Novel Anti-CD37 Beta-Particle Emitting Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma

(177)Lu-DOTA-HH1 ((177)Lu-HH1) is a novel anti-CD37 radioimmunoconjugate developed to treat non-Hodgkin lymphoma. Mice with subcutaneous Ramos xenografts were treated with different activities of (177)Lu-HH1, (177)Lu-DOTA-rituximab ((177)Lu-rituximab) and non-specific (177)Lu-DOTA-IgG(1) ((177)Lu-Ig...

Descripción completa

Detalles Bibliográficos
Autores principales: Repetto-Llamazares, Ada H. V., Larsen, Roy H., Patzke, Sebastian, Fleten, Karianne G., Didierlaurent, David, Pichard, Alexandre, Pouget, Jean Pierre, Dahle, Jostein
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4466226/
https://www.ncbi.nlm.nih.gov/pubmed/26066655
http://dx.doi.org/10.1371/journal.pone.0128816

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4466226/
https://www.ncbi.nlm.nih.gov/pubmed/26066655
http://dx.doi.org/10.1371/journal.pone.0128816

Ejemplares similares